In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nuron Biotech Inc.

www.nuronbiotech.com

Latest From Nuron Biotech Inc.

Appointments: ThermiGen, ReForm Biologics, Hookipa Biotech and Faron

This week’s roundup includes high-level appointments by Almirall, Hookipa Biotech and RXi Pharmaceuticals, in addition to CEO appointments by Karolinska Development and ReForm Biologics and various board announcements by companies including Faron and Redx.

Appointments BioPharmaceutical

Start-Up Execs On The Move, November 2013

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

BioPharmaceutical Medical Device

Biopharma Dealmaking Quarterly Statistics, Q4 2012

At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.

BioPharmaceutical Deals

Start-Up Quarterly Statistics, Q4 2012

Start-ups raised a total of $670.3 million across all industries in Q4 2012, just $11.6 million less than in Q3, and 90% of that money went to biopharma companies. Several start-up companies inked deals with Big Pharmas, and there were three acquisitions – two in biopharma and one in the device sector.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Immune Disorders
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Nuron Biotech Inc.
  • Senior Management
  • Warren D Cooper, Interim Pres. & CEO
    Daniel Cushing, PhD, SVP, R&D
    Robert J Caso, VP, Fin. & Admin.
  • Contact Info
  • Nuron Biotech Inc.
    Phone: (610) 968-6700
    1 E. Uwchlan Ave.
    Ste. 302
    Exton, PA 19341
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register